March 30, 2006 -- Maribavir from ViroPharma prevented any incidence of CMV in a Phase II trial involving transplant patients; Amgen and its soon-to-be subsidiary Abgenix completed their filing for approval of panitumumab, their colorectal cancer drug; Genentech and Biogen Idec filed to have Rituxan approval extended to another form of non-Hodgkin’s lymphoma; Aspreva Pharma completed enrolment in the third Phase III trial of CellCept; Pharmacopeia will discover small molecule drugs for GlaxoSmithKline; Pharmion applied for approval to administer Vidaza via IV; and Novartis filed for FDA approval of Galvus, a once-daily oral treatment for type 2 diabetes. The Centient Biotech 200™ closed 2 points higher at 3966.08, a rise of .05%. More details...
